通过M2离子通道阻断剂对抗流感A病毒:最新进展和局限性
Gautam Kumar1, Kakade Aditi Sakharam1
1Department of Natural Products, Chemical Sciences, National Institute of Pharmaceutical Education and Research-Hyderabad, Hyderabad, Balanagar, 500037, India.
European journal of medicinal chemistry
|February 8, 2024
概括
由于基因变化,流感病毒对治疗具有挑战性. 本综述探讨了M2蛋白抑制剂和新化合物,以对抗抗性流感菌株.
科学领域:
- 病毒学 病毒学
- 药物发现 药物发现 药物发现
- 结构生物学 结构生物学
背景情况:
- 流感疫情带来了重大的全球健康挑战,病毒遗传多态化和疫苗开发障碍使其复杂化.
- 目前的治疗方法由于获得的耐药性而面临局限性,需要新的治疗策略.
- M2蛋白离子通道对于流感病毒复制至关重要,因此它成为抗病毒疗法的关键标.
研究的目的:
- 为提供抗流感治疗的概述,重点关注M2离子通道.
- 讨论M2蛋白的结构,功能和机制及其在病毒复制中的作用.
- 要突出最近发现的化合物对野生类型和突变的M2蛋白具有潜在活性.
主要方法:
- 对抗流感疗法和M2蛋白研究的文献综述.
- 与病毒复制相关的M2蛋白结构和功能的分析.
- 识别和讨论针对M2蛋白变体的新型化学支架.
主要成果:
- 确立了M2蛋白作为流感A病毒的关键标,对病毒复制至关重要.
- 审查了现有的M2抑制剂 (阿曼塔丁,里曼塔丁) 的作用机制及其由于耐药性的局限性.
- 确定了新型化合物支架,证明了对野生类型和耐药M2蛋白质变体的活性.
结论:
- M2蛋白仍然是开发新的抗流感药物的重要目标.
- 现有的M2抑制剂因广泛的耐药性而受到损害,这强调了需要替代治疗的需要.
- 新发现的向M2蛋白的化合物为开发有效抗生素来对抗各种流感A病毒菌株提供了有希望的替代品.
关键词:
流感 A 是一种流感.M2 抑制剂的使用M2 离子通道的离子通道在M2-S31NN中使用.M2-V27A 是一个M2-V27A在M2-WTT中,它是M2-WTT.抗流感药物 抗流感药物 抗流感药物更多相关视频
相关概念视频
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
744
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
744
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
996
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
996
02:28Leaky Scanning
5.1K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.1K
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
832
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
832
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
1.8K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
1.8K